AVEO Prices Public Offering of Common Stock

  AVEO Prices Public Offering of Common Stock

Business Wire

CAMBRIDGE, Mass. -- January 17, 2013

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an
underwritten public offering of 6,667,000 shares of its common stock at a
price of $7.50 per share to the public. All of the shares are being sold by
AVEO. The gross proceeds to AVEO from this offering are expected to be
approximately $50.0 million, before deducting underwriting discounts and
commissions, and other estimated offering expenses payable by AVEO. The
offering is expected to close on or about January 23, 2013, subject to the
satisfaction of customary closing conditions.

J.P. Morgan Securities LLC is acting as sole book-running manager for the
offering, with RBC Capital Markets, LLC and Canaccord Genuity Inc. acting as
co-lead managers. AVEO has granted the underwriters a 30-day option to
purchase up to an additional 1,000,050 shares of common stock to cover
over-allotments, if any.

A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above was filed with the Securities and
Exchange Commission (the "SEC") and is effective. The offering is being made
by means of a prospectus and related prospectus supplement. Copies of the
prospectus supplement may be obtained, when available, from the offices of
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204).

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other

About AVEO

AVEO (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering,
developing and commercializing targeted therapies to impact patients' lives.
AVEO Pharmaceuticals, Inc. conducts business as AVEO Oncology.

Forward-looking Statements

Certain of the statements made in this press release are forward-looking, such
as those, among others, relating to our expectations regarding the completion
of the proposed public offering. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include, without
limitation, risk and uncertainties related to whether or not we will be able
to raise capital through the sale of shares of common stock, market and other
conditions, the satisfaction of customary closing conditions related to the
proposed public offering and the impact of general economic, industry or
political conditions in the United States or internationally. There can be no
assurance that we will be able to complete the proposed public offering on the
anticipated terms, or at all. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this press
release. Additional risks and uncertainties relating to the proposed offering,
AVEO and our business can be found under the heading “Risk Factors” included
in AVEO’s current report on Form 8-K filed with the SEC on January 16, 2013
and in the preliminary prospectus supplement related to the proposed offering
filed with the SEC on or about the date hereof, and in other filings that AVEO
periodically makes with the SEC. In addition, the forward-looking statements
included in this press release represent our views as of the date of this
press release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we specifically
disclaim any obligation to do so. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent to the date
of this press release.


AVEO Oncology
Investor Contact:
Monique Allaire, 617-299-5810
Media Contact:
Rob Kloppenburg, 617-299-5655
Press spacebar to pause and continue. Press esc to stop.